InDex and Parexel to Collaborate in Phase 2b CONDUCT Study of Kappaproct for UC

InDex and Parexel to Collaborate in Phase 2b CONDUCT Study of Kappaproct for UC
InDex Pharmaceuticals and the contract research organization (CRO) Parexel are partnering to manage the overseas Phase 2b CONDUCT dose optimization clinical trial of Kappaproct (cobitolimod) for the treatment of moderate to severe active ulcerative colitis (UC). Based on the contract between the companies, the first patient in the CONDUCT study will be enrolled during the second quarter of 2017, with topline data expected in late 2018. CONDUCT is a double-blind, placebo-controlled trial that will evaluate the safety and effectiveness of Kappaproct compared to a placebo in 215 patients with left-sided moderate to severe act
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *